Cytalux

Chemical Namepafolacianine
Dosage FormInjection (intravenous; 3.2 mg/1.6 mL (2 mg/mL))
Drug ClassImaging agents
SystemFemale reproductive
CompanyOn Target Laboratories
Approval Year2021

Indication

  • Indicated as an adjunct for intraoperative identification of malignant lesions in adult patients with ovarian cancer
Last updated on 3/15/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Cytalux (pafolacianine) Prescribing Information.2021Fisher Clinical Services Inc., Allentown, PA
Document TitleYearSource
OTL38 for intra-operative imaging of folate receptor positive ovarian cancer. 2022U.S. National Library of Medicine